Nutrition therapy program for obesity and diabetes in low-income individuals
Official title: Feasibility Study of an Intensive Nutrition Therapy Program for Improvement of Obesity and Diabetes in a Low-income Population
Run by Massachusetts General Hospital · NCT05799222 · Data updated 2026-11-12
This study tests a special meal replacement program to see if it helps low-income people with obesity and diabetes lose weight and manage their blood sugar better.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Massachusetts General Hospital Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Status | Recruiting |
| Started | March 28, 2023 |
| Main results expected | November 8, 2026 |
| Study ends | November 10, 2026 |
| Registry record updated | December 24, 2025 |
| Trial ID | NCT05799222 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are low-income adults aged 18-65 with a BMI of 27 or higher and elevated blood sugar levels.
✕Probably not a fit
Patients currently using certain diabetes medications or planning bariatric surgery may not benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the effectiveness of a medically intensive nutritional therapy program, specifically using meal replacements, for weight loss and blood sugar control in low-income individuals with obesity and diabetes. Conducted at Massachusetts General Hospital, the program provides a structured low-calorie diet to assist participants who struggle with self-directed weight management. The study will also investigate reasons for program discontinuation among participants.
Why it matters
Potential benefit: If successful, this program could provide an effective weight loss and diabetes management solution for low-income patients.
How similar studies have gone: Other studies have shown promise in using meal replacements for weight management and diabetes control, indicating potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18-65 * Body mass index (BMI) greater than or equal to 27 kg/m\^2 * HgA1C greater than or equal to 5.7 percent or fasting glucose greater than or equal to 100mg/dL within the previous 6 months * Low-income as defined by having a family income at or below 400 percent of the federal poverty level guidelines for 2022 Exclusion Criteria: * Current use of antihyperglycemic agents (other than metformin) or approved anti- obesity medications or plans to start such regimens over the 3 months post-study enrollment * HbA1c greater than or equal to 10 percent * Plans to pursue bariatric surgery over the 6 months post-study enrollment * Weight loss of greater than 5 kg within the previous 3 months * Current active eating disorder, with the exception of binge eating disorder * Severe active psychiatric disease or significant cognitive impairment deemed by investigator likely to impede adherence to piloted intervention * Active illicit substance abuse * Pregnant, breastfeeding, or considering pregnancy within the next 6 months * Current participation in another clinical research trial deemed by investigator to conflict with current study
Where it's running
-
Massachusetts General Hospital
Boston, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: Chika V Anekwe, MD — Massachusetts General Hospital
- Study coordinator: Chika V Anekwe, MD
- Email: canekwe@mgh.harvard.edu
- Phone: 617-726-4400
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Survey to determine eligibility for cardiovascular and obesity clinical trials
This study is trying to see if people with heart issues or obesity can join new clinical trials by having them fill out a survey and undergo some health checks.
-
Berobenatide for knee pain in adults who are overweight or with obesity
This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.
-
Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists
This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.
-
EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes
This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.
-
Monthly dose of PF-08653944 vs placebo in Chinese adults who are overweight or obese
This study tests whether berobenatide (PF-08653944) given once a month helps adults in China lose weight compared with a placebo.
-
FutureShape Family: a family-based weight-management program with semaglutide for children and parents
This trial tests whether a family-centered program that combines a prescription medication (semaglutide) with lifestyle support and app-based coaching can help adults with obesity and their children who are overweight/obese.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.